Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment / Advanced Radiotherapy Techniques · Journal article
Frontiers in Urology · September 7, 2026
Encouraging direction, but not yet definitive.
This retrospective case series reports that PSMA-PET-guided stereotactic body radiotherapy in 60 patients with nodal and bone oligo-recurrent prostate cancer achieved 89.7% local control with minimal acute and late toxicity, and delayed androgen-deprivation therapy initiation to a median of 32 months. The study lacks a control comparator and prospective design, and does not report whether survival outcomes differ from standard-of-care approaches.
Retrospective cohort study. Patients with initial high-risk factors presenting with nodal or bone oligo-recurrent prostate cancer; ADT use was excluded at baseline. Intervention: Robotic SBRT (1–3 fractions) guided by PSMA-PET/CT for nodal and bone metastases. n = 60. Not stated.
60 patients treated for 172 metastases across 95 treatment series; 43 patients received >1 SBRT course 89.7% local control rate achieved Median ADT-free survival (ADT-FS) was 32 months; bPFS and SBRT-FS were 6 and 23 months respectively
Acute grade 1 adverse events 6.5%, late grade 1 adverse events 1.1%
SBRT may be a feasible bridging strategy to delay systemic therapy in selected patients with oligo-recurrent prostate cancer. However, the lack of a control comparator and retrospective design limit confidence in the magnitude of benefit over observation or earlier systemic therapy initiation.
A retrospective single-centre analysis of metastasis-directed SBRT in oligo-recurrent prostate cancer showing feasible local control and delayed systemic therapy, but lacking a comparator and prospective design.
As stated by the source record.
Quoted from the source exactly as published.
SBRT may be a feasible bridging strategy to delay systemic therapy in selected patients with oligo-recurrent prostate cancer. However, the lack of a control comparator and retrospective design limit confidence in the magnitude of benefit over observation or earlier systemic therapy initiation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction To provide a detailed analysis regarding survival, local control and toxicity of nodal/bone oligo-recurrent prostate cancer identified and treated with PSMA-PET/CT and robotic SBRT using a uniform dose/fractionation scheme. The use of ADT was excluded. Methods Retrospective analysis of patients with initial high-risk factors presenting with nodal/bone oligo-recurrent PCA in Ga68- or F18-PSMA-PET/CT treated with 1-3 fraction robotic SBRT. Results 60 patients/172 metastases were treated in 95 treatment series with 43 patients receiving >1 SBRT course. Median FU was 22 months. bPFS/SBRT-FS/ADT-FS was 6/23/32 months at 89.7% local control and 6.5/1.1% acute/late grade 1 AE. High PSA-nadir, initial pN1-status and longer time to PSA-nadir were predictive for worse bPFS/SBRT-FS. Discussion Metastasis-Directed-Therapy using ablative focal SBRT is effective in bridging the gap between the identification of early metastases and the initiation of palliative systemic therapy. It is a fast outpatient procedure yielding high rates of local control, free of significant toxicity and repeatable if necessary. ADT could be withheld for almost 3 years. Patients with predictors for worse outcome could be identified.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.